283 related articles for article (PubMed ID: 16724313)
1. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system.
Stöhr W; Paulides M; Bielack S; Jürgens H; Koscielniak E; Rossi R; Langer T; Beck JD
Pediatr Blood Cancer; 2007 Feb; 48(2):140-7. PubMed ID: 16724313
[TBL] [Abstract][Full Text] [Related]
2. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.
Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
Eur J Cancer; 2009 Dec; 45(18):3213-9. PubMed ID: 19850470
[TBL] [Abstract][Full Text] [Related]
3. Late effects surveillance system for sarcoma patients.
Langer T; Stöhr W; Bielack S; Paulussen M; Treuner J; Beck JD;
Pediatr Blood Cancer; 2004 Apr; 42(4):373-9. PubMed ID: 14966836
[TBL] [Abstract][Full Text] [Related]
4. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.
Stöhr W; Paulides M; Bielack S; Jürgens H; Treuner J; Rossi R; Langer T; Beck JD
Pediatr Blood Cancer; 2007 Apr; 48(4):447-52. PubMed ID: 16628552
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
6. Dose-related nephrotoxicity of carboplatin in children.
English MW; Skinner R; Pearson AD; Price L; Wyllie R; Craft AW
Br J Cancer; 1999 Sep; 81(2):336-41. PubMed ID: 10496362
[TBL] [Abstract][Full Text] [Related]
7. Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
Oberlin O; Fawaz O; Rey A; Niaudet P; Ridola V; Orbach D; Bergeron C; Defachelles AS; Gentet JC; Schmitt C; Rubie H; Munzer M; Plantaz D; Deville A; Minard V; Corradini N; Leverger G; de Vathaire F
J Clin Oncol; 2009 Nov; 27(32):5350-5. PubMed ID: 19826134
[TBL] [Abstract][Full Text] [Related]
8. Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.
Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
Pediatr Blood Cancer; 2010 Jul; 54(7):983-9. PubMed ID: 20405516
[TBL] [Abstract][Full Text] [Related]
9. Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the late effects surveillance system (LESS).
Paulides M; Kremers A; Stöhr W; Bielack S; Jürgens H; Treuner J; Beck JD; Langer T;
Pediatr Blood Cancer; 2006 Apr; 46(4):489-95. PubMed ID: 16333817
[TBL] [Abstract][Full Text] [Related]
10. Renal impairment and hypertension in brain tumor patients treated in childhood are mainly associated with cisplatin treatment.
Pietilä S; Ala-Houhala M; Lenko HL; Harmoinen AP; Turjanmaa V; Mäkipernaa A
Pediatr Blood Cancer; 2005 Apr; 44(4):363-9. PubMed ID: 15586356
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.
Skinner R; Cotterill SJ; Stevens MC
Br J Cancer; 2000 May; 82(10):1636-45. PubMed ID: 10817497
[TBL] [Abstract][Full Text] [Related]
12. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer.
Knijnenburg SL; Mulder RL; Schouten-Van Meeteren AY; Bökenkamp A; Blufpand H; van Dulmen-den Broeder E; Veening MA; Kremer LC; Jaspers MW
Cochrane Database Syst Rev; 2013 Oct; (10):CD008944. PubMed ID: 24101439
[TBL] [Abstract][Full Text] [Related]
13. [A prospective study on nephrotoxicity induced by continuous infusion of high-dose ifosfamide (15/m2)].
Ferrari S; Zolezzi C; Bacci G; Pieretti F; Iantorno D; Figus E; Pizzoferrato A
Minerva Pediatr; 1997; 49(1-2):29-37. PubMed ID: 9132558
[TBL] [Abstract][Full Text] [Related]
14. [The kidney in children under chemotherapy].
Cachat F; Guignard JP
Rev Med Suisse Romande; 1996 Dec; 116(12):985-93. PubMed ID: 9026889
[TBL] [Abstract][Full Text] [Related]
15. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
[TBL] [Abstract][Full Text] [Related]
16. Flat dosing of carboplatin is justified in adult patients with normal renal function.
Ekhart C; de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2006 Nov; 12(21):6502-8. PubMed ID: 17085665
[TBL] [Abstract][Full Text] [Related]
17. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
18. Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study.
McMahon KR; Harel-Sterling M; Pizzi M; Huynh L; Hessey E; Zappitelli M
Pediatr Nephrol; 2018 Dec; 33(12):2311-2320. PubMed ID: 30218190
[TBL] [Abstract][Full Text] [Related]
19. Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin.
Halacova M; Kotaska K; Kukacka J; Vavrova V; Kuzelova M; Ticha J; Prusa R
J Clin Pharm Ther; 2008 Aug; 33(4):409-17. PubMed ID: 18613859
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.
Loebstein R; Atanackovic G; Bishai R; Wolpin J; Khattak S; Hashemi G; Gobrial M; Baruchel S; Ito S; Koren G
J Clin Pharmacol; 1999 May; 39(5):454-61. PubMed ID: 10234592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]